摘要
通过Grayes病(GD)患者131Ⅰ治疗前后可溶性细胞凋亡相关蛋白(sFas)、肿瘤坏死因子-α(TNF-α)及可溶性 肿瘤坏死因子受体2(sTNFR2)的含量变化,研究131Ⅰ治疗与细胞凋亡的相关性及影响。用EIA法和RIA法监 测41例GD患者131Ⅰ治疗前后sFas、TNF-α和sTNFR2水平变化,根据治疗后6至8个月的临床效果,分为缓解 组27例和未缓解组14例。结果表明,治疗前,缓解组和未缓解组血清sFas、TNF-α和sTNFR2水平与对照组比 较差异有显著性(P<0．05);治疗后,缓解组血清sFas、TNF-α和sTNFR2水平与对照组比较差异无显著性(P> 0．05),未缓解组与对照组比较差异仍有显著性(P<0．05,P<0．01)。治疗前与治疗后比较,缓解组血清sFas、 TNF-α和sTNFR2差异均有显著性(P<0．01),未缓解组差异则无显著性(P>0．05)。作者认为,131Ⅰ产生的电 离辐射对患者甲状腺细胞凋亡过程产生一定影响,血清sFas、TNF-α和sTNFR2的含量变化可以作为GD患 者131Ⅰ治疗临床观测和预后判断的良好指标。
To investigate the serum concentrations of soluble Fas（sFas）, tumor necrosis factoralfa（TNF-α）and soluble TNF receptor2 （sTNFR2） before and after ^131Ⅰ treatment of patients with Graves＇ disease （GD） and evaluate the relationship between the curative effect of ^131Ⅰ and apoptosis in GD, 41 patients were divided into two groups 6-8 months after ^131Ⅰ therapy： the recovery group （n=27） and the non-recovery group （n=14）. The serum level of TNF-α was determined by RIA. The serum sFas and sTNFR2 concentrations were measured with solid phase sandwich EIA. Twenty five healthy persons were selected as controls. The results showed that serum sFas, TNF-α and sTNFR2 levels were significantly increased in two groups of patients before ^131Ⅰ treatment compared with those of the control group（P〈0.05）. After treatment, serum concentrations of sFas, TNF-α and sTNFR2 in recovery group were significantly decreased （P〈0.05）. There were significant differences between pre- and post-treatment in levels of these factors in recovery group（P〈0.05, P〈0.01 ）but no significant differences in non-recovery group（P〉0.01）. The results indicated that ^131Ⅰ therapy affects autoimmune system and apoptosis in GD. The serum concentrations of sFas, TNF-α and sTNFR2 might be implicated for assessing effectiveness of ^131Ⅰ treatment and evaluating prognosis in GD.
出处
《标记免疫分析与临床》
CAS
2005年第4期208-210,207,共4页
Labeled Immunoassays and Clinical Medicine
